Lakewood-Amedex Biotherapeutics (LABT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the S-1 for Q2 FY2026, filed Sep 18, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LABT SEC filings page.
This page shows Lakewood-Amedex Biotherapeutics Inc. (LABT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
The numbers depict a development-stage business whose financing strain now outweighs its shrinking asset base and operating investment.
Equity moved from$410K positive to-$1.96M between FY2024 and FY2025, indicating liabilities overwhelmed the asset base. The current ratio fell from 1.5x to 0.1x, while financing cash flow accompanied negative operating cash flow in FY2025; the balance sheet became more dependent on outside funding.
R&D fell
FY2025 liabilities of
Financial Health Signals
We do not publish a peer-relative financial health score for Lakewood-Amedex Biotherapeutics Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Lakewood-Amedex Biotherapeutics Inc.'s EBITDA was -$3.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Lakewood-Amedex Biotherapeutics Inc. reported a net loss of $3.8M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Lakewood-Amedex Biotherapeutics Inc. earned -$2.75 per diluted share (EPS) in Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Lakewood-Amedex Biotherapeutics Inc. held $2.6M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Lakewood-Amedex Biotherapeutics Inc.'s quarterly ROE was -87.1% in Q2 2026: one quarter's net income over shareholder equity, not annualized.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Lakewood-Amedex Biotherapeutics Inc. invested $503K in research and development in Q2 2026. This represents an increase of 242.4% from the same quarter a year earlier. Against the prior quarter it is up 176.2%.
Not reported for Q2 2026.
Not reported for Q2 2026.
LABT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-1 | Q1'26S-1 | Q4'25S-1 | Q2'25S-1 | Q1'25S-1 | Q4'24S-1 |
|---|---|---|---|---|---|---|
| Cost of Revenue | N/A | $507K | N/A | N/A | N/A | N/A |
| R&D Expenses | $503K+242.4% | $182K+7.3% | N/A | $147K | $170K | N/A |
| SG&A Expenses | $3.3M+571.4% | $703K+89.2% | N/A | $489K | $372K | N/A |
| Operating Income | -$3.8Mn/m | -$887Kn/m | N/A | -$637K | -$543K | N/A |
| EBITDA | -$3.8Mn/m | -$886Kn/m | N/A | -$636K | -$541K | N/A |
| Interest Expense | $11K-55.6% | $38K+2806.4% | N/A | $24K | $1K | N/A |
| Net Income | -$3.8Mn/m | -$923Kn/m | N/A | -$656K | -$540K | N/A |
| EPS (Basic) | -$2.75 | -$0.20n/m | N/A | -$1.66 | -$0.15 | N/A |
| EPS (Diluted) | -$2.75 | -$0.20n/m | N/A | -$1.66 | -$0.15 | N/A |
| Diluted Shares (Avg) | 1M | 7M+0.7% | N/A | 694,450 | 7M | N/A |
Not reported in any period shown, so not listed: Revenue, Gross Profit, Income Tax.
LABT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-1 | Q1'26S-1 | Q4'25S-1 | Q2'25S-1 | Q1'25S-1 | Q4'24S-1 |
|---|---|---|---|---|---|---|
| Total Assets | $5.0M | $196K | $482K-55.0% | N/A | N/A | $1.1M |
| Current Assets | $4.8M | $51K | $305K-60.5% | N/A | N/A | $774K |
| Cash & Equivalents | $2.6M+103.8% | $12K-97.5% | $236K-65.3% | $1.3M | $477K | $681K |
| Short-Term Investments | $2.0Mn/m | $0n/m | $0n/m | $0 | $0 | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 |
| Total Liabilities | $629K | $3.0M | $2.4M+270.1% | N/A | N/A | $661K |
| Current Liabilities | $629K | $3.0M | $2.4M+380.4% | N/A | N/A | $501K |
| Non-Current Liabilities | $0 | $10K | $41K-74.4% | N/A | N/A | $160K |
| Total Equity | $4.3Mn/m | -$2.8Mn/m | -$2.0M-579.6% | -$683K | -$76K | $410K |
| Retained Earnings | -$68.6M | -$54.3M | -$53.4Mn/m | N/A | N/A | -$49.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
LABT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
LABT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$2.0M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.13), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. LABT | FY2025 | N/A | N/A | N/A | $991K | — |
| Valion Bio, Inc. VBIO | FY2025 | N/A | -$8.9M | N/A | $1.1M | — |
| Artelo Biosciences, Inc. ARTL | FY2025 | N/A | -$12.9M | N/A | $1.2M | — |
| Matinas BioPharma Holdings, Inc. MTNB | FY2025 | N/A | -$10.3M | N/A | $1.2M | — |
| Scinai Immunotherapeutics Ltd. SCNI | FY2025 | $1.3M | -$8.3M | N/A | $1.3M | 54/100 |
| Virax Biolabs Group Limited VRAX | FY2026 | $12K | -$5.0M | N/A | $866K | — |
Where Lakewood-Amedex Biotherapeutics Inc. Ranks
Frequently Asked Questions
Lakewood-Amedex Biotherapeutics Inc. (LABT) recorded an outflow of $1.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Lakewood-Amedex Biotherapeutics Inc. (LABT) had $482K in total assets as of fiscal year 2025, including both current and long-term assets.
Lakewood-Amedex Biotherapeutics Inc. (LABT) invested $1.3M in research and development during fiscal year 2025.
Lakewood-Amedex Biotherapeutics Inc. (LABT) had a current ratio of 0.13 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Lakewood-Amedex Biotherapeutics Inc. (LABT) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $991K as of Nov 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Lakewood-Amedex Biotherapeutics Inc. (LABT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $991K as of Nov 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Lakewood-Amedex Biotherapeutics Inc. (LABT) held $236K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.9M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Lakewood-Amedex Biotherapeutics Inc. (LABT) has negative shareholder equity of -$2.0M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.